IL6 and rheumatoid arthritis: The novel disease-modifying antirheumatic drug, T-614, has a reported effect on preventing the inflammatory and destructive processes of RA by inhibiting the production of immunoglobulins and various inflammatory cytokines (IL-1, IL-6, IL-8, and TNF-α), exerting a unique mechanism for RA therapy [18].